Polly Niravath, M.D.
Houston Methodist Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Polly Niravath, M.D. as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 11:54 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT03820141 · Durvalumab With Trastuzumab and Pertuzumab in HER2-Enriched Breast CancerThe Methodist Hospital Research Institute · active not recruiting · Breast Cancer · principal investigator
- Ph1NCT03742245 · Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast CancerThe Methodist Hospital Research Institute · active not recruiting · Breast Cancer Metastatic, Breast Cancer · principal investigator
- Ph1/Ph2NCT02834403 · L-NMMA Plus Taxane Chemotherapy in Refractory Locally Advanced or Metastatic Triple Negative Breast Cancer PatientsThe Methodist Hospital Research Institute · completed · Metastatic Triple Negative Breast Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 11:54 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name in breast cancer.